BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 29776968)

  • 1. Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons.
    Adams JM; Pei H; Sandoval DA; Seeley RJ; Chang RB; Liberles SD; Olson DP
    Diabetes; 2018 Aug; 67(8):1538-1548. PubMed ID: 29776968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.
    Frikke-Schmidt H; Hultman K; Galaske JW; Jørgensen SB; Myers MG; Seeley RJ
    Mol Metab; 2019 Mar; 21():13-21. PubMed ID: 30685336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus.
    Knudsen LB; Secher A; Hecksher-Sørensen J; Pyke C
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):56-63. PubMed ID: 27186357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats.
    Fortin SM; Lipsky RK; Lhamo R; Chen J; Kim E; Borner T; Schmidt HD; Hayes MR
    Sci Transl Med; 2020 Mar; 12(533):. PubMed ID: 32132220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
    Secher A; Jelsing J; Baquero AF; Hecksher-Sørensen J; Cowley MA; Dalbøge LS; Hansen G; Grove KL; Pyke C; Raun K; Schäffer L; Tang-Christensen M; Verma S; Witgen BM; Vrang N; Bjerre Knudsen L
    J Clin Invest; 2014 Oct; 124(10):4473-88. PubMed ID: 25202980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice.
    Burmeister MA; Ayala JE; Smouse H; Landivar-Rocha A; Brown JD; Drucker DJ; Stoffers DA; Sandoval DA; Seeley RJ; Ayala JE
    Diabetes; 2017 Feb; 66(2):372-384. PubMed ID: 27908915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression.
    Wagner S; Brierley DI; Leeson-Payne A; Jiang W; Chianese R; Lam BYH; Dowsett GKC; Cristiano C; Lyons D; Reimann F; Gribble FM; Martinez de Morentin PB; Yeo GSH; Trapp S; Heisler LK
    Mol Metab; 2023 Feb; 68():101665. PubMed ID: 36592795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo.
    Dong Y; Carty J; Goldstein N; He Z; Hwang E; Chau D; Wallace B; Kabahizi A; Lieu L; Peng Y; Gao Y; Hu L; Betley JN; Williams KW
    Mol Metab; 2021 Dec; 54():101352. PubMed ID: 34626854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The acute anorexic effect of liraglutide, a GLP-1 receptor agonist, does not require functional leptin receptor, serotonin, and hypothalamic POMC and CART activities in mice.
    Nonogaki K; Kaji T
    Diabetes Res Clin Pract; 2016 Oct; 120():186-9. PubMed ID: 27585115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
    Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
    BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.
    Iepsen EW; Zhang J; Thomsen HS; Hansen EL; Hollensted M; Madsbad S; Hansen T; Holst JJ; Holm JC; Torekov SS
    Cell Metab; 2018 Jul; 28(1):23-32.e3. PubMed ID: 29861388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets.
    Le TDV; Fathi P; Watters AB; Ellis BJ; Besing GK; Bozadjieva-Kramer N; Perez MB; Sullivan AI; Rose JP; Baggio LL; Koehler J; Brown JL; Bales MB; Nwaba KG; Campbell JE; Drucker DJ; Potthoff MJ; Seeley RJ; Ayala JE
    Mol Metab; 2023 Jun; 72():101718. PubMed ID: 37030441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
    Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide, a GLP-1 Receptor Agonist, Which Decreases Hypothalamic 5-HT2A Receptor Expression, Reduces Appetite and Body Weight Independently of Serotonin Synthesis in Mice.
    Nonogaki K; Kaji T
    J Diabetes Res; 2018; 2018():6482958. PubMed ID: 29484303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight.
    Anderberg RH; Richard JE; Eerola K; López-Ferreras L; Banke E; Hansson C; Nissbrandt H; Berqquist F; Gribble FM; Reimann F; Wernstedt Asterholm I; Lamy CM; Skibicka KP
    Diabetes; 2017 Apr; 66(4):1062-1073. PubMed ID: 28057699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.